Govind Rajagopalan
DownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Titles
Associate Research Scientist
Appointments
Pulmonary, Critical Care & Sleep Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Govind Rajagopalan's published research.
Publications Timeline
A big-picture view of Govind Rajagopalan's research output by year.
Buqu Hu
Jon Koff, MD
Gail Stanley, MD, MPH
Vaidehi R. Chowdhary, MBBS, MD
Asawari Korde
Brian Clark, MD
73Publications
1,199Citations
Publications
2024
Epidermal Growth Factor Receptor Regulates Beclin-1 in Hyperoxia-Induced Lung Injury
Harris Z, Sun Y, Korde A, Hu B, Sharma L, Manning E, Joerns J, Clark B, Stanley G, Shin H, Placek L, Unutmaz D, Chun H, Sauler M, Rajagopalan G, Zhang X, Wang H, Kang M, Koff J. Epidermal Growth Factor Receptor Regulates Beclin-1 in Hyperoxia-Induced Lung Injury. 2024, a6841-a6841. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6841.Peer-Reviewed Original ResearchRole of Staphylococcus Aureus Superantigens in Cystic Fibrosis Lung Inflammation
Rajagopalan G, Tolentino J, Sun Y, Hu B, Koff J. Role of Staphylococcus Aureus Superantigens in Cystic Fibrosis Lung Inflammation. 2024, a6673-a6673. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6673.Peer-Reviewed Original ResearchOptimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University
Würstle S, Lee A, Kortright K, Winzig F, An W, Stanley G, Rajagopalan G, Harris Z, Sun Y, Hu B, Blazanin M, Hajfathalian M, Bollyky P, Turner P, Koff J, Chan B. Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Scientific Reports 2024, 14: 2657. PMID: 38302552, PMCID: PMC10834462, DOI: 10.1038/s41598-024-52192-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEvolutionary selection pressurePhage characterizationPhage therapyPersistent bacterial infectionsBacteriophage therapyPhageSelection pressurePseudomonas aeruginosaInvestigational new drug applicationBacterial infectionsNew Drug ApplicationTherapyDrug applicationClinical applicationAutographiviridaeBacteriaPotential strategy
2023
Protracted Pulmonary Inflammation in IFN-gamma Deficient Mice Recovering From Cytokine Release Syndrome
Rajagopalan G, Sun Y, Hu B, Harris Z, Stanely G, Koff J. Protracted Pulmonary Inflammation in IFN-gamma Deficient Mice Recovering From Cytokine Release Syndrome. 2023, a1386-a1386. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1386.Peer-Reviewed Original ResearchA Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections
Geyer J, Krupa K, Harris Z, Sun Y, Sharma L, Würstle S, Hu B, Stanley G, Rajagopalan G, Pellot E, Koff J, Robinson J. A Novel Zinc (II) Porphyrin Is Synergistic with PEV2 Bacteriophage against Pseudomonas aeruginosa Infections. Antibiotics 2023, 12: 735. PMID: 37107097, PMCID: PMC10135120, DOI: 10.3390/antibiotics12040735.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMinimum inhibitory concentrationMinimum bactericidal concentrationCystic fibrosisAntiviral activityPseudomonas aeruginosa infectionLife-threatening infectionsAntibiotic-resistant infectionsDose-dependent responsePulmonary infectionPotent bactericidal activityAeruginosa infectionMouse lungPsA populationImmune systemVivo modelLung cellsPSA cellsHealth concernNovel therapeuticsInfectionLung modelH441 cellsOpportunistic bacterial pathogenSignificant decreaseInhibitory concentration
2020
Contribution of Staphylococcal Enterotoxin B to Staphylococcus aureus Systemic Infection
Bae J, Da F, Liu R, He L, Lv H, Fisher E, Rajagopalan G, Li M, Cheung G, Otto M. Contribution of Staphylococcal Enterotoxin B to Staphylococcus aureus Systemic Infection. The Journal Of Infectious Diseases 2020, 223: 1766-1775. PMID: 32937658, PMCID: PMC8161638, DOI: 10.1093/infdis/jiaa584.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStaphylococcal enterotoxin BS. aureus pathogenesisCommunity-associated methicillin-resistant S. aureus infectionsMethicillin-resistant S. aureus infectionsEnterotoxin BS. aureus infectionMouse infection modelDrug development strategiesCytokine stormFatal exacerbationStaphylococcus aureus systemic infectionSuperantigenic toxinsAureus infectionMajor human pathogenST59 isolatesSystemic infectionInfection modelVirulence potentialInfectionStaphylococcus aureusPathogenesisHuman pathogensSEBExacerbationIsolatesIL-17A and IFN-gamma Play Distinct Roles in Pulmonary and Extrapulmonary Acute Respiratory Distress Syndrome Induced by a Staphylococcal Superantigen
Rajagopalan G, Coutermarsh-Ott S, Sun Y, Hu B, Harris Z, Stanley G, Koff J. IL-17A and IFN-gamma Play Distinct Roles in Pulmonary and Extrapulmonary Acute Respiratory Distress Syndrome Induced by a Staphylococcal Superantigen. 2020, a7708-a7708. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7708.Peer-Reviewed Original Research
2019
Lack of correlation of virulence gene profiles of Staphylococcus aureus bacteremia isolates with mortality
Park K, Greenwood-Quaintance K, Cunningham S, Rajagopalan G, Chia N, Jeraldo P, Mandrekar J, Patel R. Lack of correlation of virulence gene profiles of Staphylococcus aureus bacteremia isolates with mortality. Microbial Pathogenesis 2019, 133: 103543. PMID: 31102653, DOI: 10.1016/j.micpath.2019.103543.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAgedAged, 80 and overAnimalsBacteremiaBacterial AdhesionBase SequenceCell ProliferationDrug Resistance, BacterialFemaleHLA-DR3 AntigenHumansImmune EvasionMaleMethicillin-Resistant Staphylococcus aureusMiceMice, TransgenicMiddle AgedMinnesotaPolymerase Chain ReactionStaphylococcal InfectionsStaphylococcus aureusSuperantigensVirulenceVirulence FactorsConceptsMethicillin-susceptible S. aureusS. aureus bacteremiaAureus bacteremiaMedical CenterHLA-DR3 transgenic miceStaphylococcus aureus bacteremiaMinnesota Medical CenterLarge medical centerImmune evasion genesVirulence genesVirulence gene profilesNumber of deathsClinical dataClinical valueTransgenic miceClinical practiceIndividual PCR assaysWhole-genome sequencing analysisMortalitySAg genesSurvivorsLack of correlationBacteremiaWGS analysisFunctional assaysRuxolitinib, a selective JAK1/2 inhibitor, for the treatment of serious diseases caused by Staphylococcus aureus superantigens
Carnes H, Mehrkens B, Stegman M, Rajagopalan G. Ruxolitinib, a selective JAK1/2 inhibitor, for the treatment of serious diseases caused by Staphylococcus aureus superantigens. The Journal Of Immunology 2019, 202: 190.34-190.34. DOI: 10.4049/jimmunol.202.supp.190.34.Peer-Reviewed Original ResearchConceptsSystemic inflammatory response syndromeMulti-organ failureT cellsHLA-DR3 transgenic miceHLA class II moleculesVehicle-treated miceVivo studiesInflammatory response syndromeT cell subsetsToxic shock syndromeJAK 1/2 inhibitorSelective JAK1/2 inhibitorClass II moleculesStaphylococcus aureusDose-dependent mannerSerious diseaseJanus kinaseIL-17Response syndromeOrgan failureJAK1/2 inhibitorActivation markersCell subsetsShock syndromeIL-2
2018
Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease
Miyabe K, Zen Y, Cornell LD, Rajagopalan G, Chowdhary VR, Roberts LR, Chari ST. Gastrointestinal and Extra-Intestinal Manifestations of IgG4–Related Disease. Gastroenterology 2018, 155: 990-1003.e1. PMID: 30012334, DOI: 10.1053/j.gastro.2018.06.082.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIgG4-RDPlasma cellsExtra-intestinal manifestationsHuman IgG4-RDSimilar immune reactionsRelapsing-remitting courseDense lymphoplasmacytic infiltrateTiters of autoantibodiesMulti-organ diseasePermanent organ damageObliterative phlebitisStoriform fibrosisAutoimmune etiologyMetachronous lesionsPrimary therapyExcellent prognosisLymph nodesLymphoplasmacytic infiltrateSerum levelsOrgan damageSerum IgG4Bile ductAutoimmune diseasesTypical presentationInflammatory response